# Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

> **NCT00755885** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cancer Research UK** · enrollment: 77 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** abiraterone acetate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT00755885
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2016-06-04
- **Final completion:** 2016-06-04
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2017-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755885, "Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00755885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*